Ten lessons from the EMPEROR‐Reduced trial
Sign Up to like & getrecommendations! Published in 2020 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.2009
Abstract: 1Department of Medicine, University of Mississippi Medical Center, Jackson, MS, USA; 2Université de Lorraine, Inserm INI-CRCT, CHRU, Nancy, France; 3National and Kapodistrian University of Athens School of Medicine, Athens University Hospital Attikon, Athens, Greece; 4Department… read more here.
Keywords: medicine; lessons emperor; reduced trial; university ... See more keywords
Early changes in estimated glomerular filtration rate post‐initiation of empagliflozin in EMPEROR‐Reduced
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Heart Failure"
DOI: 10.1002/ejhf.2578
Abstract: Sodium–glucose cotransporter 2 inhibitors (SGLT2i) may induce an early post‐initiation decrease of estimated glomerular filtration rate (eGFR), which does not impact the SGLT2i benefits. The occurrence, characteristics, determinants, and clinical significance of an initial eGFR… read more here.
Keywords: glomerular filtration; filtration rate; estimated glomerular; post initiation ... See more keywords
SGLT2 inhibitors in patients with heart failure with reduced ejection fraction: a meta-analysis of the EMPEROR-Reduced and DAPA-HF trials
Sign Up to like & getrecommendations! Published in 2020 at "The Lancet"
DOI: 10.1016/s0140-6736(20)31824-9
Abstract: BACKGROUND Both DAPA-HF (assessing dapagliflozin) and EMPEROR-Reduced (assessing empagliflozin) trials showed that sodium-glucose co-transporter-2 (SGLT2) inhibition reduced the combined risk of cardiovascular death or hospitalisation for heart failure in patients with heart failure with reduced… read more here.
Keywords: heart; cardiovascular death; emperor reduced; heart failure ... See more keywords